Compounded vs Brand-Name GLP-1: The Legal and Practical Difference, May 2026

Brand-name and compounded GLP-1s are not the same product behind a different label. The active molecule is the same when a compounder uses semaglutide base, but the manufacturing, QA, delivery device, and legal pathway are all different. One of those differences, the salt-form issue, is what FDA has been writing warning letters about for nine months.

This article is for patients choosing between a compounded prescription and a brand-name one in mid-2026. We will not tell you which to pick. We lay out what each one is, what has been tested, what FDA has flagged, what the price difference is now, and what to ask your prescriber.

The basic difference

Brand-name GLP-1s are FDA-approved finished products. Wegovy and Ozempic are semaglutide manufactured by Novo Nordisk; Zepbound and Mounjaro are tirzepatide manufactured by Eli Lilly. Each was the subject of a new-drug application that included pivotal efficacy trials, animal toxicology, human pharmacokinetics, manufacturing-process validation, and sterility testing. The approved indication, dose range, and titration schedule sit on the FDA-approved label (Wegovy; Zepbound).

Compounded GLP-1s are something else. A state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility buys bulk active pharmaceutical ingredient, combines it with excipients, fills it into vials, and ships it under a patient-specific prescription. There is no FDA pre-market review of the finished compounded product. The active ingredient is, in principle, the same molecule; the rest of the dosage form is whatever the compounder makes it.

That structural difference, finished-product review versus ingredient-level compounding, drives every question that follows.

The legal pathway: why compounded GLP-1s existed at all

Compounding is legal but tightly bounded. The Federal Food, Drug, and Cosmetic Act §§503A and 503B permit pharmacies to compound a copy of an FDA-approved drug in two main situations: when the drug is on the FDA Drug Shortages list, or under §503A(b)(1)(D), when a state-licensed pharmacist compounds for an identified patient because the prescriber has documented a clinically meaningful change from the approved product.

From 2022 through early 2025, the shortage pathway powered the compounded market. FDA added the semaglutide products in August 2022 and tirzepatide in December 2022; hundreds of US compounders began producing copies, distributed through telehealth at $199–$299/month. FDA declared the tirzepatide shortage resolved on October 2, 2024 and semaglutide on February 21, 2025; every enforcement-discretion deadline had passed by May 22, 2025. The full sequence sits on our regulatory timeline.

What remains legal in May 2026 is compounding under §503A(b)(1)(D), the personalised-dose pathway, also the pathway under active FDA scrutiny. Our 503A vs 503B pharmacy guide explains what each framework can and cannot do in 2026.

What's in the bottle

The active-ingredient question has three layers.

Same molecule, in principle. Semaglutide base is the same 31-amino-acid peptide whether it ends up in Wegovy or in a compounded semaglutide vial; tirzepatide base is the same molecule whether it ends up in Zepbound or in a compounded tirzepatide vial. The chemistry, at the API level, is not the differentiator.

Excipients differ. Inactive ingredients (preservatives, tonicity agents, buffers, sometimes added B12) are decided by the compounder, not by the FDA-approved label. The brand products have a fixed excipient list that has been through formal stability and biocompatibility testing. A compounded product's list is the compounder's call.

Salt forms. This is the active issue. FDA states on its unapproved GLP-1 concerns page that some compounders sell semaglutide sodium and semaglutide acetate, salt forms that are not the active ingredient in Wegovy or Ozempic. FDA says it is "not aware of any lawful basis" for compounding from these salts, and "does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug." The issue is cited in the GLP-1 Solution warning letter and across the fifty-plus letters of September 2025.

Separately, the QA regime differs. Brand manufacturing runs under FDA-inspected cGMP. 503B facilities are FDA-registered and subject to cGMP-like inspections; 503A pharmacies are state-licensed and not. The variance across compounders is real.

What's NOT in either

Neither a brand nor a compounded prescription is, on its own, a weight-loss programme. The pen or vial contains a drug. It does not contain nutrition coaching, behavioural support, a documented off-ramp protocol, or insurance navigation. Patients sometimes pay 5x for a bundled "weight loss" offering versus cash-pay Wegovy through NovoCare, and the differential is almost entirely the wraparound services.

Whichever drug ends up in your fridge, the things that move a five-year outcome (diet, resistance training, sleep, the taper) are what your prescriber's subscription does or does not give you.

What patients are actually confused about

Patient forums on r/Ozempic and r/Semaglutide surface three recurring questions that the marketing copy for both brand and compounded products systematically fails to answer.

"How do I know it's reputable?" A highly upvoted r/Ozempic thread from a prospective patient captures the core confusion: "I keep seeing people talk about things like bulk options, or different clinics claiming to be the best semaglutide provider or best tirzepatide provider, but I don't know what's actually worth using. I'm more concerned about scams, inconsistent medication, or clinics pushing low-quality compounded products." This is a legitimate question. The markers worth asking about are covered in our five-question framework below: which legal pathway, which 503A/503B compounder, which salt form.

"Is the compounded version as good as the brand?" Patients who have used compounded products and lost substantial weight — 60, 80, 90 pounds — tend to report that the drug worked. The absence of a head-to-head clinical trial does not mean compounded products do not work for individual patients; it means there is no population-level evidence comparable to STEP-1 or SURMOUNT-1. The things that make the question genuinely difficult are the salt-form issue (semaglutide sodium versus semaglutide base) and the vial-versus-pen dosing differential, not whether the molecule itself is pharmacologically active.

"What happens if the compounded market closes?" Patients mid-treatment reasonably worry about supply continuity. The honest answer is that the personalised-dose pathway under §503A(b)(1)(D) is in active litigation and could narrow further. Brand-name NovoCare pricing has fallen significantly since 2024; for most doses, switching from compounded to brand now means a price differential of under $100–$150 per month. The switch plan question to put to your prescriber is whether you would titrate from scratch or continue at your current equivalent dose.

Cost, May 2026

The price gap has narrowed dramatically since 2024.

• Wegovy cash-pay through Novo Nordisk's NovoCare Pharmacy: $349/month ($199 introductory for the 0.25 mg and 0.5 mg starter doses).
• Zepbound vials through Eli Lilly's LillyDirect: $299/month at 2.5 mg, $399/month at 5 mg, $449/month at higher doses (CNBC).
• Compounded semaglutide via Mochi, Henry Meds, Fella, Willow and similar platforms: typically $199–$299/month. Hims exited compounded GLP-1 marketing under its March 9, 2026 settlement with Novo Nordisk — see the compounding cliff timeline for the saga.

At several doses the differential is now under $100/month. In 2023 it was closer to $1,000. That collapse is part of why the regulatory cliff matters less to most patients' wallets than it did a year ago. For a broader look at every legal low-cost option, see our cheap GLP-1 alternatives guide. Brand pricing in detail sits on Wegovy cash-pay through NovoCare and Zepbound vials through LillyDirect.

Clinical evidence: what's been studied

The pivotal trials tested the brand finished product. Semaglutide 2.4 mg was evaluated in the STEP series; STEP-1 (Wilding et al., NEJM 2021) reported an average 14.9% weight loss at 68 weeks (PubMed). Tirzepatide was evaluated in the SURMOUNT series; SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported an average 22.5% weight loss at 72 weeks at 15 mg (PubMed).

There is no head-to-head RCT comparing brand and compounded semaglutide, or brand and compounded tirzepatide. A reasonable patient can infer that the active ingredient, when it is the FDA-approved base form, at the same dose, with comparable bioavailability, should produce similar effects. That is a reasonable inference; it is not a tested one. Where the API is a salt form, or the concentration differs materially from the brand product, the inference is weaker.

The honest summary: the efficacy you read about for "semaglutide" or "tirzepatide" is the efficacy of the brand product as tested; the efficacy of a compounded equivalent is reasonable to assume in most cases and untested at the trial level in all cases.

Safety signal: what FDA has flagged

FDA's page on unapproved GLP-1 drugs flags four categories.

Dosing errors. Brand pens meter the dose by the device; compounded products are typically multi-dose vials drawn with an insulin syringe. As of April 30, 2025, FDA had received 520 adverse-event reports for compounded semaglutide and 480 for compounded tirzepatide, likely undercounted because 503A pharmacies are not required to file MedWatch reports (UIC Drug Information Group). Some patients drew 5 to 20 times the intended dose, where instructions specified "units" instead of milligrams. Hospitalisations have been documented.

Salt forms. Covered above.

Misleading marketing. FDA's September 2025 warning letter to Hims & Hers cites claims that compounded products contained "the same active ingredient as Ozempic and Wegovy" without the approved-product safety information, framing those claims as misbranding. Fifty-plus similar letters went out the same week.

Counterfeit product. FDA has separately warned about counterfeit semaglutide where the named compounding pharmacy does not exist or the active ingredient does not match the label.

This is not a verdict on the whole compounded category. Many 503A and 503B compounders operate cleanly. It is a verdict on the variance, and on what FDA pre-market review of the finished brand product buys for patients who pay for it.

The legal status in May 2026

Mass-market compounding under the shortage carve-out is over. What remains is §503A(b)(1)(D): a state-licensed pharmacist may compound for an identified patient when the prescriber documents that a change from the FDA-approved product produces "a significant difference" for that patient. Examples that arguably qualify: a non-commercial dose between approved strengths during a clinical taper, a documented intolerance to an inactive ingredient, or a clinically justified combination.

"Compounded" in 2026 almost always means under this framing, and the framing is itself in active litigation. Novo Nordisk's February 2026 patent suit named Hims plus fourteen other firms (CNBC); Hims settled on March 9, 2026 and exited compounded GLP-1 marketing (HMP Global), but the other defendants remain in litigation. The OFA tirzepatide appeal is pending in the Fifth Circuit, and FDA's April 30, 2026 proposal would keep all three GLP-1s off the permanent 503B bulks list.

How to think about the choice as a patient

Five concrete things are worth weighing. Phrase each one as a question to your prescriber in writing.

1. Active ingredient. "Is this semaglutide base, sodium, or acetate?" Brand products are base; salt forms are flagged by FDA as having no known lawful compounding basis.
2. Legal pathway. "Which pathway is this filled under: the shortage list, §503A(b)(1)(D) personalisation, or something else?" If the answer is "the shortage", it is out of date.
3. Delivery device. "Is the dose pre-set in the device, or do I draw it from a multi-dose vial?" Pens versus draw-your-own vials is the single biggest factor in dosing-error risk.
4. Compounder identity. "Which 503A pharmacy or 503B outsourcing facility prepares this product, and what is its inspection history?" Not all compounders are alike.
5. Backup plan. "If FDA enforcement or a court ruling forces this product off the market, what is the switch plan?" The compounded channel has narrowed twice in 18 months.

Our methodology page covers how we evaluate these answers in provider reviews; the provider comparison applies the same frame across telehealth platforms. For the underlying pharmacology, see how GLP-1 drugs work.

How we keep this article current

We recheck the legal frame on this page monthly, because the regulatory picture moves faster than the pharmacology. The mechanism content on how GLP-1 drugs work is, by contrast, settled science. The parts most likely to drift before our next review:

• The personalised-dose pathway under §503A(b)(1)(D). A federal-court ruling, a final FDA guidance, or a Fifth Circuit decision in the OFA tirzepatide appeal could close or narrow it with little notice.
• The salt-form question. If FDA finalises a position that semaglutide salts are adulterated APIs, the products containing them disappear from the legal compounded market the next day.

If you spot an error or a missing source, email [email protected]. We acknowledge within five business days and publish the resolution within fifteen.

Methodology: this article reports the regulatory, manufacturing, and clinical-trial status of brand and compounded GLP-1 receptor agonist drugs as of May 27, 2026, based on FDA labels, FDA safety pages, FDA warning letters, peer-reviewed trial publications, and manufacturer disclosures. It is not medical advice and does not recommend brand over compounded or vice versa. The article is editorial-only; our medical reviewer has not yet signed off on individual clinical claims. See editorial policy and methodology.